Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.

Jeppesen PB, Pertkiewicz M, Messing B, Iyer K, Seidner DL, O'keefe SJ, Forbes A, Heinze H, Joelsson B

Gastroenterology11 Sept 2012Cited by 348 (Europe PMC)

PMID22982184DOI10.1053/j.gastro.2012.09.007PepBankPUB-22982184

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In SBS-IF patients, responders were more frequent with teduglutide (27/43, 63%) than placebo (13/43, 30%; P = .002).
In plain wordsIn SBS-IF patients, teduglutide produced more parenteral support volume responders than placebo.
Peptide
Teduglutide
Outcome
IncreaseParenteral support volume responders
Study
n = 86
Comparator
Placebo
Analysis
Primary
Outcome group
Parenteral support · Gastrointestinal
Studied dose
0.05 mg/kg/d once daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Responders (>20% reduction in parenteral support volume at weeks 20 and 24)
63%
teduglutide 0.05 mg/kg/d, 27/43
Responders (>20% reduction in parenteral support volume at weeks 20 and 24)
30%
placebo, 13/43
Source sentences
Summary
There were significantly more responders in the teduglutide group (27/43 [63%]) than the placebo group (13/43 [30%]; P = .002).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary efficacy end point was number of responders (patients with >20% reduction in parenteral support volume from baseline at weeks 20 and 24).
Summary · context
We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily.
Report a problemFND-2298218401
02HumanNon-randomized trialEfficacy outcome
In SBS-IF patients, a 1-day or greater weekly support reduction occurred in 21/39 (54%) with teduglutide versus 9/39 (23%) with placebo (P = .005).
In plain wordsIn SBS-IF patients, more teduglutide recipients than placebo recipients reduced weekly support needs by at least one day.
Peptide
Teduglutide
Outcome
IncreasePatients with a 1-day or more weekly reduction in parenteral support
Study
n = 78
Comparator
Placebo
Outcome group
Parenteral support · Gastrointestinal
Studied dose
0.05 mg/kg/d once daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Patients with 1-day or more weekly reduction in parenteral support
54%
teduglutide group, 21/39
Patients with 1-day or more weekly reduction in parenteral support
23%
placebo group, 9/39
Source sentences
Summary
The percentage of patients with a 1-day or more reduction in the weekly need for parenteral support was greater in the teduglutide group (21/39 [54%]) than in the placebo group (9/39 [23%]; P = .005).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily.
Report a problemFND-2298218403
03HumanNon-randomized trialEfficacy outcome
In SBS-IF patients, parenteral support volume fell by 4.4 ± 3.8 L/wk with teduglutide versus 2.3 ± 2.7 L/wk with placebo (P < .001).
In plain wordsIn SBS-IF patients, teduglutide reduced parenteral support volume more than placebo at week 24.
Peptide
Teduglutide
Outcome
DecreaseParenteral support volume reduction at week 24
Study
n: not reported in source
Comparator
Placebo
Outcome group
Parenteral support · Gastrointestinal
Studied dose
0.05 mg/kg/d once daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Mean reduction in parenteral support volume at week 24
4.4 L/wk
teduglutide group, SD 3.8, baseline 12.9 ± 7.8 L/wk
Mean reduction in parenteral support volume at week 24
2.3 L/wk
placebo group, SD 2.7, baseline 13.2 ± 7.4 L/wk
Source sentences
Summary
At week 24, the mean reduction in parenteral support volume in the teduglutide group was 4.4 ± 3.8 L/wk (baseline 12.9 ± 7.8 L/wk) compared with 2.3 ± 2.7 L/wk (baseline 13.2 ± 7.4 L/wk) in the placebo group (P < .001).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily.
Report a problemFND-2298218402
04HumanNon-randomized trialEfficacy outcome
In SBS-IF patients, teduglutide increased plasma citrulline concentrations, a biomarker of mucosal mass.
In plain wordsIn SBS-IF patients, teduglutide increased blood citrulline levels, a marker of intestinal mucosal mass.
Peptide
Teduglutide
Outcome
IncreasePlasma citrulline concentration
Study
n: not reported in source
Outcome group
Intestinal adaptation · Gastrointestinal
Studied dose
0.05 mg/kg/d once daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Teduglutide increased plasma concentrations of citrulline, a biomarker of mucosal mass.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily.
Report a problemFND-2298218404
05HumanNon-randomized trialSafety outcome
In SBS-IF patients, adverse events leading to discontinuation had a similar distribution with teduglutide (n = 2) and placebo (n = 3).
In plain wordsIn SBS-IF patients, adverse events leading to discontinuation had a similar distribution with teduglutide and placebo.
Peptide
Teduglutide
Outcome
Direction not reportedTreatment-emergent adverse events leading to discontinuation
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.05 mg/kg/d once daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Patients with treatment-emergent adverse events leading to study discontinuation
2 patients
teduglutide group
Patients with treatment-emergent adverse events leading to study discontinuation
3 patients
placebo group
Source sentences
Summary
The distribution of treatment-emergent adverse events that led to study discontinuation was similar between patients given teduglutide (n = 2) and placebo (n = 3).
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a 24-week study of patients with SBS-IF who were given subcutaneous teduglutide (0.05 mg/kg/d; n = 43) or placebo (n = 43) once daily.
Report a problemFND-2298218405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedEarly phase 1NCT04290429

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

University of Freiburgn = 66 Dec 2017 to 6 Dec 2019

Graft Versus Host Disease

Trial page ClinicalTrials.govUpdated 29 Nov 2023

CompletedPhase 3Results postedNCT00798967

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

Shiren = 8625 Nov 2008 to 25 Jan 2011

Short Bowel Syndrome

Trial page ClinicalTrials.govUpdated 3 Jun 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.